Form 4: BioMarin Director Enyedy Acquires and Disposes of Shares in Recent Transaction

Director Mark J Enyedy reports acquisition and disposal of BioMarin Pharmaceutical Inc. shares on May 21, 2024, according to a Form 4 filing.

Summary

• On May 21, 2024, Mark J Enyedy, a director of BioMarin Pharmaceutical Inc., engaged in transactions involving the company's common stock.
• Enyedy acquired 4,720 shares of common stock at a price of $0, and disposed of 6,900 shares.
• Following these transactions, Enyedy directly owns 6,900 shares of BioMarin Pharmaceutical Inc.
• The acquisition involved restricted stock units granted on May 21, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of company directors and officers, which can sometimes provide insights into their perspectives on the company's prospects.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company directors as it can provide insights into their confidence in the company's future performance.

Key Dates